Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study

• Published in: Annals of intensive care 2023-12, Vol.13 (1), p.123-123, Article 123
• Main Authors: Baucher, Louise, Lemiale, Virginie, Joseph, Adrien, Wallet, Florent, Pineton de Chambrun, Marc, Ferré, Alexis, Lombardi, Romain, Platon, Laura, Contejean, Adrien, Fuseau, Charline, Calvet, Laure, Pène, Frédéric, Kouatchet, Achille, Mokart, Djamel, Azoulay, Elie, Lafarge, Antoine
• Format: Article
• Language: English
• Subjects: Anesthesiology; Aspergillosis; Chemotherapy; Critical Care Medicine; Emergency Medicine; Ibrutinib; Infections; Inhibitor drugs; Intensive; Intensive care; Lymphoproliferative disease; Medicine; Medicine & Public Health; Mortality; Opportunistic infections; Targeted cancer therapy; Targeted drugs; Ventilators
• ISSN: 2110-5820; 2110-5820
• DOI: 10.1186/s13613-023-01219-5

Background In the last decade, Ibrutinib has become the standard of care in the treatment of several lymphoproliferative diseases such as chronic lymphocytic leukemia (CLL) and several non-Hodgkin lymphoma. Beyond Bruton tyrosine kinase inhibition, Ibrutinib shows broad immunomodulatory effects that may promote the occurrence of infectious complications, including opportunistic infections. The infectious burden has been shown to vary by disease status, neutropenia, and prior therapy but data focusing on severe infections requiring intensive care unit (ICU) admission remain scarce. We sought to investigate features and outcomes of severe infections in a multicenter cohort of 69 patients receiving ibrutinib admitted to 10 French intensive care units (ICU) from 1 January 2015 to 31 December 2020. Results Median time from ibrutinib initiation was 6.6 [3–18] months. Invasive fungal infections (IFI) accounted for 19% (n = 13/69) of severe infections, including 9 (69%; n = 9/13) invasive aspergillosis, 3 (23%; n = 3/13) Pneumocystis pneumonia, and 1 (8%; n = 1/13) cryptococcosis. Most common organ injury was acute respiratory failure (ARF) (71%; n = 49/69) and 41% (n = 28/69) of patients required mechanical ventilation. Twenty (29%; n = 20/69) patients died in the ICU while day-90 mortality reached 55% (n = 35/64). In comparison with survivors, decedents displayed more severe organ dysfunctions (SOFA 7 [5–11] vs. 4 [3–7], p = 0.004) and were more likely to undergo mechanical ventilation (68% vs. 31%, p = 0.010). Sixty-three ibrutinib-treated patients were matched based on age and underlying malignancy with 63 controls receiving conventional chemotherapy from an historic cohort. Despite a higher median number of prior chemotherapy lines (2 [1–2] vs. 0 [0–2]; p